Management of oral anticoagulant treatment in patients with venous thromboembolism

Seminars in Thrombosis and Hemostasis

Volumn 32, Issue 8, 2006, Pages 781-786

  Pengo, Vittorio ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b Ospedale Busonera   (Italy)

Author keywords

Laboratory control; Management; Oral anticoagulants; Venous thromboembolism; Warfarin

Indexed keywords

ACENOCOUMAROL; ACETYLSALICYLIC ACID; AMIODARONE; ANTICOAGULANT AGENT; CARBAMAZEPINE; CIMETIDINE; CIPROFLOXACIN; COTRIMOXAZOLE; DANAZOL; ERYTHROMYCIN; FIBRIC ACID DERIVATIVE; FLUCONAZOLE; ISONIAZID; METRONIDAZOLE; MICONAZOLE; NAFCILLIN; OMEPRAZOLE; PHENOBARBITAL; PHENYLBUTAZONE; PHENYTOIN; PIROXICAM; PROPAFENONE; PROPRANOLOL; RIFAMPICIN; SIMVASTATIN; SUCRALFATE; TAMOXIFEN; TETRACYCLINE; UNINDEXED DRUG; WARFARIN;

ANTICOAGULATION; BLEEDING; BLOOD CLOTTING; DOSE RESPONSE; DRUG CHOICE; DRUG EFFICACY; DRUG SAFETY; HUMAN; INTERNATIONAL NORMALIZED RATIO; PRIORITY JOURNAL; PROTHROMBIN TIME; REVIEW; RISK ASSESSMENT; THROMBOEMBOLISM; VENOUS THROMBOEMBOLISM;

ADMINISTRATION, ORAL; ANTICOAGULANTS; BLOOD COAGULATION; DRUG MONITORING; HEMORRHAGE; HUMANS; INTERNATIONAL NORMALIZED RATIO; MONITORING, PHYSIOLOGIC; PROTHROMBIN TIME; THROMBOEMBOLISM;

EID: 33845621054     PISSN: 00946176     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2006-955460     Document Type: Review

References (22)

1. Suttie JW. Vitamin K antagonists. In: Colman RW, Hirsh J, Marder VJ, Salzman EW, eds. Hemostasis and Thrombosis. Philadelphia, PA: Lippincott; 1994:1565
2. Thijssen HHW, Hamulyàk K, Willigers H. 4-Hydroxycoumarin oral anticoagulants: pharmacokinetics-response relationships. Thromb Haemost 1988;60:35-38
3. Hull RD, Delmore T, Genton E, et al. Warfarin sodium versus low-dose heparin in the long-term treatment of venous thrombosis. N Engl J Med 1979;302:855-858
4. Hull R, Delmore T, Carter C, et al. Adjusted subcutaneous heparin versus warfarin sodium in the long-term treatment of venous thrombosis. N Engl J Med 1982;306:189-194
5. Caprini JA, Arcelus JI, Reyna JJ, et al. Deep vein thrombosis outcome and the level of oral anticoagulation therapy. J Vasc Surg 1999;30:805-811
6. Ridker PM, Goldhaber SZ, Danielson E, et al. PREVENT Investigators. Long-term, low-intensity warfarin therapy for the prevention of recurrent venous thromboembolism. N Engl J Med 2003;348:1425-1434
7. Kearon C, Ginsberg JS, Kovacs MJ, et al. Extended Low-Intensity Anticoagulation for Thrombo-Embolism Investigators. Comparison of low-intensity warfarin therapy with conventional-intensity warfarin therapy for long-term prevention of recurrent venous thromboembolism. N Engl J Med 2003;349:631-639
8. Streiff MB. Vena caval filters: a comprehensive review. Blood 2000;95:3669-3677
9. Palareti G, Legnani C, Lee A, et al. A comparison of the safety and efficacy of oral anticoagulation for the treatment of venous thromboembolic disease in patients with or without malignancy. Thromb Haemost 2000;84:805-810
10. Harrison L, Johnston M, Massicotte MP, Crowther M, Moffat K, Hirsh J. Comparison of 5-mg and 10-mg loading doses in initiation of warfarin therapy. Ann Intern Med 1997;126:133-136
11. Tait RC, Sefcick A. A warfarin induction regimen for outpatient anticoagulation in patients atrial fibrillation. Br J Haematol 1998;101:450-454
12. Barcellona D, Vannini ML, Fenu L, Balestrieri C, Marongiu F. Warfarin or acenocoumarol: which is better in the management of oral anticoagulants? Thromb Haemost 1998;80:899-902
13. Callus A, Jackaman J, Tillet J, Mills W, Wycherley A. Safety and efficacy of warfarin started early after submassive venous thrombosis or pulmonary embolism. Lancet 1986;ii:1293-1296
14. Hirsh J, Fuster V. Guide to anticoagulant therapy. Part 1: heparin. Circulation 1994;89:1449-1468
15. Hull RD, Raskob GE, Rosenbloom E, et al. Heparin for 5 days as compared with 10 days in the initial treatment of proximal venous thrombosis. N Engl J Med 1990;322:1260-1264
16. Hyers TM, Agnelli G, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest 2001;119:176S-193S
17. Pengo V, Banzato A, Garelli E, Zasso A, Biasiolo A. Reversal of excessive effect of regular anticoagulation: low oral dose of phytonadione (vitamin K1) compared with warfarin discontinuation. Blood Coagul Fibrinolysis 1993;4:739-741
18. Crowther MA, Julian J, McCarty D, et al. Treatment of warfarin-associated coagulopathy with oral vitamin K: a randomised controlled trial. Lancet 2000;356:1551-1553
19. Panneerselvam S, Baglin C, Lefort W, Baglin T. Analysis of risk factors for over-anticoagulation in patients receiving long-term warfarin. Br J Haematol 1998;103:422-424
20. Palareti G, Legnani C, Guazzaloca G, et al. Ad hoc Study Group of the Italian Federation of Anticoagulation Clinics. Risk factors for highly unstable response to oral anti-coagulation: a case-control study. Br J Haematol 2005;129:72-78
21. Wells PS, Holbrook AM, Crowther NR, Hirsh J. Interaction of warfarin with drugs and food. Ann Intern Med 1994;121:676-683
22. Pemgo V, Finazzi G, Testa S, Tripodi Aon behalf of the Italian Federation of Anticoagulation Clinics. Self-testing and self-monitoring of oral anticoagulant therapy: consensus of the Italian Federation of Anticoagulation Clinics. Haematologica 2003;88(suppl 3):1-10